Value Adjusted for Debt and Cash: Cara Therapeutics Inc (CARA)
Cara Therapeutics, Inc. (CARA) focuses on developing treatments for pruritus in patients with renal failure, as evidenced by the price action visualized on GURU.Markets, where the Enterprise Value stands at -5.06. Drug deliveries are carried out through a network of specialized clinics. However, failed late-stage trials have undermined market advantages and investor confidence, effectively destroying the business's moat.
Cara Therapeutics, Inc. - analytical breakdowns and key metrics (CARA)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Capital Cara Therapeutics, Inc.|CARA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital caratherapeutics.com|CARA - Company Debts|Debt to Net Assets Ratio Cara Therapeutics|CARA - Company Long-Term Debt|Short-Term Debt Cara Therapeutics|Quick Liquidity Indicator caratherapeutics.com
- business earnings and investment ratios data:
Analysis of all company metrics:Cara Therapeutics Inc.
The development of biopharmaceutical antipruritic drugs in compliance with ESG standards and bioethics is reflected in the dynamics of the business's fundamental value. This metric determines the real buyout price of Cara Therapeutics, Inc. (CARA) by summing the market capitalization with net debt (liabilities minus cash), allowing investors to objectively assess the asset by excluding market volatility and identifying the true enterprise value.
Competitors of Cara Therapeutics, Inc. (CARA)
Enterprise Value Biogen Inc BIIB|NBIX - Total Company Value|Value Adjusted for Debt and Cash RGC (Regencell Corp)|AXSM: Enterprise Value|acadia-pharm.com (ACAD) - Enterprise Value|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|AVXL (Anavex Life Sciences) - Enterprise Value|Real Price to Acquire Entire Company ceribell.com (CBLL)|Enterprise Value PRTA|Enterprise Value alector.com (ALEC)|Total Company Value Annexon Inc. ANNX|Value Adjusted for Debt and Cash OMER|Neurogene Inc. - Enterprise Value|ACIU - Enterprise Value|VYGR (Voyager Therapeutics, Inc.) - Real Price to Acquire Entire Company|Neumora - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company SCLX|TVGN (Tevogen Bio Inc.) - Aggregate Business Value|Enterprise Value ACOG|CGTX (Cognition Therapeutics Inc.) - Value Adjusted for Debt and Cash|Enterprise Value IKT (Inhibikase Therapeutics, Inc.)|Cassava Sciences Inc (SAVA) - Total Enterprise Value|ASRT - Total Company Value|Value Adjusted for Debt and Cash COYA (Coya Therapeutics, Inc.)|VTGN: Enterprise Value|Ovid Therapeutics (OVID) - Enterprise Value|Total Company Value Acumen Pharmaceuticals, Inc.|CervoMed, Inc. - Full Business Value|Enterprise Value ATHE|CLNN - Total Enterprise Value|PepGen - Real Price to Acquire Entire Company|Enterprise Value Jupiter Neurosciences, Inc. JUNS|RLMD: Real Price to Acquire Entire Company|Annovis Bio Inc - Aggregate Business Value|GRCE: Enterprise Value|AIFF - Company Buyout Price|KLTO (ANEW Medical) - Enterprise Value|Real Price to Acquire Entire Company NeuroSense Therapeutics, Ltd. (NRSN)|Total Company Value Reviva Pharmaceuticals Holdings, Inc. (RVPH)|Company Buyout Price metaviatx.com|NeurAxis, Inc - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash HSDT|Passage Bio Corp - Enterprise Value|Company Buyout Price Neuphoria Therapeutics Inc. NEUP|Minerva Neurosciences, Inc. (NERV) - Total Company Value|Business Value ATHA|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value|Real Price to Acquire Entire Company Alzamend (ALZN)|Real Price to Acquire Entire Company CYCN (Cyclerion Therapeutics)|Company Buyout Price protagenic.com|Enterprise Value KTTA (Pasithea Therapeutics Corp.)|CRGT - Real Price to Acquire Entire Company|Avenue Therapeutics, Inc - Enterprise Value|BCLI - Enterprise Value|Chromocell Therapeutics (CHRO) - Total Company Value|Eliem Therapeutics Inc. - Value Adjusted for Debt and Cash|ITCI (Intra-Cellular Therapies Inc.) - Enterprise Value|Enterprise Value Longboard Pharmaceuticals Inc|Total Company Value Marinus (MRNS)|NKGen Biotech Corp - Business Value|Enterprise Value NRBO (NeuroBo Pharmaceuticals)|sagerx.com (SAGE) - Total Enterprise Value|SNPX: Real Price to Acquire Entire Company|TRVN - Enterprise Value|vigilneuro.com (VIGL) - Total Company Value|anewmeds.com - Value Adjusted for Debt and Cash|Total Company Value Cerevel Therapeutics